Supernus Pharmaceuticals annual total liabilities
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Total Liabilities Growth & History (SUPN)
Supernus Pharmaceuticals's total liabilities was $390.9M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $390.9M | $58.6M | +17.63% |
| 2024 | 2024-12-31 | $332.3M | −$23.8M | −6.69% |
| 2023 | 2023-12-31 | $356.2M | −$460.1M | −56.37% |
| 2022 | 2022-12-31 | $816.3M | −$57.0M | −6.53% |
| 2021 | 2021-12-31 | $873.3M | $114.1M | +15.02% |
| 2020 | 2020-12-31 | $759.2M | $194.4M | +34.41% |
| 2019 | 2019-12-31 | $564.9M | $40.1M | +7.63% |
| 2018 | 2018-12-31 | $524.8M | $367.8M | +234.29% |
| 2017 | 2017-12-31 | $157.0M | $39.2M | +33.25% |
| 2016 | 2016-12-31 | $117.8M | $17.2M | +17.09% |
| 2015 | 2015-12-31 | $100.6M | $4.5M | +4.72% |
| 2014 | 2014-12-31 | $96.1M | $18.6M | +23.93% |
| 2013 | 2013-12-31 | $77.5M | $41.1M | +112.89% |
| 2012 | 2012-12-31 | $36.4M | −$7.9M | −17.77% |
| 2011 | 2011-12-31 | $44.3M | — | — |
Supernus Pharmaceuticals quarterly total liabilities
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $396.9M | $78.4M | +24.61% |
| Q1 2026 | 2026-03-31 | $423.9M | $107.3M | +33.90% |
| Q4 2025 | 2025-12-31 | $390.9M | $58.6M | +17.63% |
| Q3 2025 | 2025-09-30 | $370.1M | $34.5M | +10.29% |
| Q2 2025 | 2025-06-30 | $318.5M | −$39.9M | −11.13% |
| Q1 2025 | 2025-03-31 | $316.6M | −$58.3M | −15.56% |
| Q4 2024 | 2024-12-31 | $332.3M | −$23.8M | −6.69% |
| Q3 2024 | 2024-09-30 | $335.6M | −$37.4M | −10.03% |
| Q2 2024 | 2024-06-30 | $358.4M | −$14.8M | −3.97% |
| Q1 2024 | 2024-03-31 | $374.9M | −$504.7M | −57.38% |
| Q4 2023 | 2023-12-31 | $356.2M | −$460.1M | −56.37% |
| Q3 2023 | 2023-09-30 | $373.0M | −$467.4M | −55.62% |
| Q2 2023 | 2023-06-30 | $373.2M | −$480.3M | −56.28% |
| Q1 2023 | 2023-03-31 | $879.7M | $68.6M | +8.46% |
| Q4 2022 | 2022-12-31 | $816.3M | −$57.0M | −6.53% |
| Q3 2022 | 2022-09-30 | $840.3M | $95.8M | +12.86% |
| Q2 2022 | 2022-06-30 | $853.5M | $66.1M | +8.39% |
| Q1 2022 | 2022-03-31 | $811.1M | $58.1M | +7.71% |
| Q4 2021 | 2021-12-31 | $873.3M | $114.1M | +15.02% |
| Q3 2021 | 2021-09-30 | $744.6M | −$56.6M | −7.06% |
| Q2 2021 | 2021-06-30 | $787.5M | −$37.6M | −4.55% |
| Q1 2021 | 2021-03-31 | $753.0M | $176.5M | +30.62% |
| Q4 2020 | 2020-12-31 | $759.2M | $194.4M | +34.41% |
| Q3 2020 | 2020-09-30 | $801.1M | $251.5M | +45.75% |
| Q2 2020 | 2020-06-30 | $825.0M | $284.3M | +52.57% |
| Q1 2020 | 2020-03-31 | $576.5M | $31.1M | +5.69% |
| Q4 2019 | 2019-12-31 | $564.9M | $40.1M | +7.63% |
| Q3 2019 | 2019-09-30 | $549.7M | $49.1M | +9.80% |
| Q2 2019 | 2019-06-30 | $540.8M | $78.5M | +16.97% |
| Q1 2019 | 2019-03-31 | $545.4M | $72.1M | +15.24% |
| Q4 2018 | 2018-12-31 | $524.8M | $367.8M | +234.29% |
| Q3 2018 | 2018-09-30 | $500.6M | $366.8M | +274.08% |
| Q2 2018 | 2018-06-30 | $462.3M | $345.3M | +295.23% |
| Q1 2018 | 2018-03-31 | $473.3M | $357.1M | +307.34% |
| Q4 2017 | 2017-12-31 | $157.0M | $39.2M | +33.25% |
| Q3 2017 | 2017-09-30 | $133.8M | $22.1M | +19.75% |
| Q2 2017 | 2017-06-30 | $117.0M | $8.6M | +7.90% |
| Q1 2017 | 2017-03-31 | $116.2M | $18.8M | +19.34% |
| Q4 2016 | 2016-12-31 | $117.8M | $17.2M | +17.09% |
| Q3 2016 | 2016-09-30 | $111.7M | $23.7M | +26.91% |
| Q2 2016 | 2016-06-30 | $108.4M | $56.6M | +109.27% |
| Q1 2016 | 2016-03-31 | $97.4M | $52.3M | +116.11% |
| Q4 2015 | 2015-12-31 | $100.6M | $4.5M | +4.72% |
| Q3 2015 | 2015-09-30 | $88.1M | $27.8M | +46.25% |
| Q2 2015 | 2015-06-30 | $51.8M | −$9.0M | −14.83% |
| Q1 2015 | 2015-03-31 | $45.1M | −$23.5M | −34.24% |
| Q4 2014 | 2014-12-31 | $96.1M | $18.6M | +23.93% |
| Q3 2014 | 2014-09-30 | $60.2M | — | — |
| Q2 2014 | 2014-06-30 | $60.8M | −$35.3M | −36.70% |
| Q1 2014 | 2014-03-31 | $68.5M | $30.7M | +81.29% |
| Q4 2013 | 2013-12-31 | $77.5M | $41.1M | +112.89% |
| Q2 2013 | 2013-06-30 | $96.1M | $54.1M | +128.85% |
| Q1 2013 | 2013-03-31 | $37.8M | −$5.1M | −11.97% |
| Q4 2012 | 2012-12-31 | $36.4M | −$7.9M | −17.77% |
| Q3 2012 | 2012-09-30 | $42.4M | — | — |
| Q2 2012 | 2012-06-30 | $42.0M | — | — |
| Q1 2012 | 2012-03-31 | $42.9M | — | — |
| Q4 2011 | 2011-12-31 | $44.3M | — | — |
Supernus Pharmaceuticals total liabilities trends
Over the last five fiscal years, Supernus Pharmaceuticals's total liabilities decreased from $759.2M to $390.9M, a change of −$368.3M. The latest reported quarter, Q2 2026, shows $396.9M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
